Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability Study of Subcutaneous Abatacept New Process J vs Current Process F in Healthy Participants
NCT05981976Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2023
- Primary completion
- Dec 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of abatacept in rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) and psoriatic arthritis (PsA) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed serum concentration at Day 71, Area under the serum concentration-time curve from time zero to the last time of quantifiable concentration at Day 71 and 1 more. Started Aug 2023; status: completed.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)juvenile idiopathic arthritis (JIA)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT05981976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05981976.